% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • system_architect_enterprise system_architect_enterprise Nov 11, 2013 7:14 AM Flag

    The FDA Letter is also making stuff up

    The FDA Letter goes quite a bit beyond what was said, and just starts making up stuff about what the CEO said. The FDA Letter states:

    "Furthermore, the statements made regarding Juxtapid misleadingly suggest that
    Juxtapid is safe and effective as a monotherapy"

    Yet nothing the CEO said would indicate Juxtapid as a monotherapy. The FDA is going far out on a limb by pretending that was what the CEO said, and this will **BACKFIRE** on the FDA.

    More to come, stay tuned, as this will prove to be a significant boomerang against the FDA.
    In the end, it will set a precedent that the FDA isn't treating AEGR fairly, and will serve as a shield against any action by the FDA against AEGR in the future.

1.73+0.12(+7.45%)May 26 4:00 PMEDT